BLA 103532 · Genentech
Pulmozyme
Dornase Alfa · Recombinant Human Deoxyribonuclease 1
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Dec 30, 1993
Approved uses
4
Original approval plus efficacy supplements
Registered trials
53
11 Phase 3, 7 recruiting
FAERS reports
19,634
13,482 serious, 827 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 17, 2025.
PULMOZYME ® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. PULMOZYME is a recombinant DNase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. ( 1 )
Mechanism: PULMOZYME is recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. In preclinical in vitro studies, PULMOZYME hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity. In CF patients, retention of viscous purulent secretions in the airways contributes both to reduced pulmonary function and to exacerbations of infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2014 Supplement 5175 · Efficacy LetterLabel
- Feb 24, 1998 Supplement 1025 · Efficacy
- Nov 27, 1996 Supplement 1018 · Efficacy
- Dec 30, 1993 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- PULMOZYME · DORNASE ALFA 1MG/ML · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dornase Alfa" as an intervention, any sponsor and status, largest first.
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
- Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase AlfaPivotal-lookingStatus unknown
University Hospital TuebingenAcademic, hospital or other
NCT00204685 · 540 participants · Start Aug 2003
Drug: dornase alfa · For: Long Term Ventilation
Sites: Tübingen, Germany; Berlin, Germany; Chemnitz, Germany · 25 sites in all
- Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe TraumaPivotal-lookingRecruiting
University Hospital, Strasbourg, FranceAcademic, hospital or other
NCT03368092 · 500 participants (planned) · Start Mar 4, 2019 · Primary completion Sep 1, 2027
Drug: Dornase Alfa Inhalant Solution [Pulmozyme]; Placebos · For: Multiple Trauma; Respiratory Distress Syndrome, Adult
Sites: Strasbourg, France
University of MelbourneAcademic, hospital or other
NCT05203224 · 330 participants · Start Feb 18, 2022 · Primary completion Nov 24, 2025
Drug: Dornase Alfa · For: Ischemic Stroke
Sites: Brisbane, Australia; Adelaide, Australia; Melbourne, Australia
- Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 MonthsPivotal-lookingRecruiting
Fondation Ophtalmologique Adolphe de RothschildResearch network
NCT06723717 · 304 participants (planned) · Start Sep 26, 2025 · Primary completion Mar 2028
Drug: Daily infusion of dornase alfa · For: Ruptured Aneurysm of Intracranial Artery; SAH (Subarachnoid Hemorrhage); Delayed Cerebral Ischemia
Sites: Grenoble, France; Lyon, France; Montpellier, France · 6 sites in all
Democritus University of ThraceAcademic, hospital or other
NCT05279391 · 150 participants (planned) · Start Oct 25, 2020 · Primary completion Nov 30, 2021
Drug: Dexamethasone; Low molecular weight heparin and 4 more · For: COVID-19 Severe Respiratory Failure
Sites: Alexandroupoli, Greece
- Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic FibrosisPivotal-lookingCompleted
AO GENERIUMIndustry
NCT04468100 · 100 participants · Start Aug 30, 2017 · Primary completion May 16, 2018
Drug: Tigerase®; Pulmozyme® · For: Cystic Fibrosis; Fibrosis
Sites: Barnaul, Russia; Ufa, Russia; Simferopol, Russia · 14 sites in all
- Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19Pivotal-lookingCompleted
AO GENERIUMIndustry
NCT04459325 · 100 participants · Start Jun 1, 2020 · Primary completion Jul 20, 2020
Drug: Tigerase® and best available care · For: COVID-19; Coronavirus Disease 2019
Sites: Moscow, Russia · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infective pulmonary exacerbation of cystic fibrosis2,316
- cystic fibrosis1,776
- hospitalisation1,320
- pneumonia1,308
- cough1,000
- off label use975
- infection950
- no adverse event944
- dyspnoea926
- condition aggravated623
- headache548
- pulmonary function test decreased494
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 15 |
| 2006 | 18 |
| 2007 | 25 |
| 2008 | 44 |
| 2009 | 28 |
| 2010 | 85 |
| 2011 | 277 |
| 2012 | 217 |
| 2013 | 240 |
| 2014 | 438 |
| 2015 | 793 |
| 2016 | 1,160 |
| 2017 | 1,288 |
| 2018 | 2,093 |
| 2019 | 3,972 |
| 2020 | 3,601 |
| 2021 | 1,263 |
| 2022 | 1,076 |
| 2023 | 848 |
| 2024 | 1,040 |
| 2025 | 662 |
| 2026 | 435 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pulmozyme (Dornase Alfa)
2024 spending
$2.0M
Beneficiaries
100
443 claims
Per beneficiary
$20,465
$50.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,236,443 |
| 2021 | $1,906,841 |
| 2022 | $2,050,467 |
| 2023 | $2,299,698 |
| 2024 | $2,046,484 |
Part B: Pulmozyme (Dornase Alfa) · HCPCS J7639
2024 spending
$23.2M
Beneficiaries
892
5,623 claims
Per beneficiary
$25,988
2024 ASP limit $52.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $31,924,225 |
| 2021 | $29,490,764 |
| 2022 | $26,071,831 |
| 2023 | $24,138,838 |
| 2024 | $23,180,890 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Claudius C, Perner A, Møller MH · Syst Rev 2015 · Comparative Study, Meta-Analysis
- Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N, Ratjen F, Russell R, et al. · Lancet Respir Med 2023 · Randomized Controlled Trial, Multicenter Study
- Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience.
Cheong XK, Ban AY, Ng BH, et al. · BMC Pulm Med 2022 · Clinical Trial
- Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey.
den Hollander B, Linssen RSN, Cortjens B, et al. · Eur J Hosp Pharm 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
Tam J, Nash EF, Ratjen F, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Alternative outcomes for the multiple breath washout in children with CF.
Stanojevic S, Jensen R, Sundaralingam D, et al. · J Cyst Fibros 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.